BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ISTO Technologies, Inc. to Present at Canaccord Genuity's Musculoskeletal Conference


2/10/2011 8:20:28 AM

ST. LOUIS, Feb. 10, 2011 /PRNewswire/ -- ISTO Technologies, Inc., a privately-held orthobiologics company, announced today that Mitchell Seyedin, Ph. D., President and Chief Executive Officer, is scheduled to present at Canaccord Genuity's Musculoskeletal Conference to be held at the Westin San Diego on February 15, 2011 at 10:00 AM (PT). The conference, directly preceding the American Academy of Orthopedic Surgeons Annual Meeting, will feature presentations from over 60 public and private companies.

ISTO's proprietary cell-based orthobiologic platform harnesses the regenerative capacity of juvenile cartilage cells to create products designed to repair and restore function to damaged tissue. The company believes that the two clinical-stage products currently comprising ISTO's cell-based program, DeNovo® ET and NuQu, potentially represent significant breakthroughs addressing two significant unmet medical needs (damaged knee cartilage and discogenic back pain). These products utilize juvenile chondrocytes that have a proven superior capacity for cartilage regeneration compared to adult cells. Additionally, ISTO's patented cell-expansion process allows for a scalable, off-the-shelf solution not possible with autologous cell-based technologies

DeNovo ET, a scaffold-free engineered cartilage tissue, is intended for the repair of damaged articular cartilage in the knee. ISTO believes the product represents a novel treatment for cartilage repair.

DeNovo ET is developed in partnership with Zimmer Inc.

NuQu is an injectable juvenile chondrocyte therapy for early intervention and restoration of disc function in patients suffering from discogenic back pain. There is currently no effective treatment for invertebral disc repair and this minimally-invasive ambulatory treatment potentially represents a breakthrough and cost-effective solution for discogenic back pain.

In addition to ISTO's cell-based cartilage programs, the company is currently producing and marketing, InQu®, a bone graft extender and substitute. InQu combines integrated hyaluronic acid and a synthetic polymer for better handling and biology. The primary target market for the product is spinal fusion applications.

About ISTO

ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at www.istotech.com.

ISTO Technologies, Inc.

Scott Gill

Chief Financial Officer

(314) 995-6049


The Ruth Group

Zack Kubow (investors)

(646) 536-7020

zkubow@theruthgroup.com


Kimberly Muscara (media)

(646) 536-7011

kmuscara@theruthgroup.com



SOURCE ISTO Technologies, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES